Comprehensive coverage on anti-mycobacterial endeavour reported during 2022

• Published in: European journal of medicinal chemistry Vol. 255; p. 115409
• Main Authors: Dhameliya, Tejas M., Vekariya, Drashtiben D., Patel, Heta Y., Patel, Janvi T.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 05.07.2023
• Subjects: Anti-TB activity; Antitubercular Agents - chemistry; Heterocyclic scaffolds; Humans; M. tuberculosis; MDR-TB; Mycobacterium; Mycobacterium tuberculosis; Mycobacterium; MDR-TB; Heterocyclic scaffolds; Anti-TB activity; M. tuberculosis
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2023.115409

TB being one of the deadliest diseases and second most common infectious cause of deaths, poses the severe threat to global health. The extended duration of therapy owing to resistance and its upsurge in immune-compromised patients have been the driving force for the development of novel of anti-TB scaffolds. Recently, we have compiled the account of anti-mycobacterial scaffolds published during 2015–2020 and updated them in 2021. The present work involves the insights on the anti-mycobacterial scaffolds reported in 2022 with their mechanism of action, structure activity relationships, along with the key perceptions for the design of newer anti-TB agents for the broader interests of medicinal chemists. [Display omitted] •Organized coverage of diversified scaffolds with anti-tubercular profile reported in 2022.•Novel heterocycles reported for anti-TB profile along with their merits and demerits.•Focused need for novel drug candidates against drug resistant strains.•Highlighted with mode of anti-TB action against M. tuberculosis strains.•Insightful discussion on their in silico, in vitro or in vivo anti-tuberculosis potential, if reported.